Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Publication
, Journal Article
Strickler, JH; Cohn, AL; Arrowood, C; Haley, S; Morse, M; Uronis, H; Blobe, GC; Hsu, SD; Zafar, Y; Hurwitz, H
Published in: Journal of Clinical Oncology
May 20, 2011
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
3586 / 3586
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Strickler, J. H., Cohn, A. L., Arrowood, C., Haley, S., Morse, M., Uronis, H., … Hurwitz, H. (2011). Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Journal of Clinical Oncology, 29(15_suppl), 3586–3586. https://doi.org/10.1200/jco.2011.29.15_suppl.3586
Strickler, J. H., A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. Uronis, G. C. Blobe, S. D. Hsu, Y. Zafar, and H. Hurwitz. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 3586–3586. https://doi.org/10.1200/jco.2011.29.15_suppl.3586.
Strickler JH, Cohn AL, Arrowood C, Haley S, Morse M, Uronis H, et al. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):3586–3586.
Strickler, J. H., et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 3586–3586. Crossref, doi:10.1200/jco.2011.29.15_suppl.3586.
Strickler JH, Cohn AL, Arrowood C, Haley S, Morse M, Uronis H, Blobe GC, Hsu SD, Zafar Y, Hurwitz H. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):3586–3586.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
3586 / 3586
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences